Scholarlink

Background <p>Trastuzumab deruxtecan (T-DXd) has demonstrated substantial clinical efficacy in patients with advanced breast cancer; however, predictive and prognostic biomarkers for treatment outcomes remain poorly defined. Host immune status has been reported to influence the efficacy of various systemic therapies, but its clinical significance in patients treated with T-DXd is not yet fully understood.</p> Methods <p>We conducted a retrospective, single-center study of patients with breast cancer who received T-DXd. Their baseline peripheral blood immune markers—including absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio—were evaluated prior to treatment initiation. Time-to-treatment failure (TTF) and overall survival (OS) were analyzed using Kaplan–Meier methods and Cox proportional hazards models.</p> Results <p>A total of 126 patients were included in the study. Univariate analyses showed that low ALC and high NLR were associated with shorter TTF and OS. In multivariate analyses adjusted for relevant clinical factors, low ALC and high NLR remained associated with shorter TTF and OS.</p> Conclusions <p>Baseline peripheral blood immune markers, particularly ALC and NLR, may be associated with clinical outcomes in patients with breast cancer treated with T-DXd. These readily available markers may have potential clinical utility and warrant further prospective validation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Baseline peripheral blood immune markers associated with clinical outcomes in patients with advanced breast cancer treated with trastuzumab deruxtecan

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月13日

查看全文
  • Akihiro Fujimoto,
  • Yuki Ichinose,
  • Kazuo Matsuura,
  • Emi Mikami,
  • Wakako Inohana,
  • Taeko Kurosawa,
  • Ayako Nakame,
  • Ayaka Sakakibara,
  • Asami Nukui,
  • Aya Asano,
  • Hiroko Shimada,
  • Hideki Yokogawa,
  • Masahiro Ohara,
  • Hiroshi Ishiguro,
  • Takahiro Hasebe,
  • Akihiko Osaki,
  • Toshiaki Saeki

摘要

Background

Trastuzumab deruxtecan (T-DXd) has demonstrated substantial clinical efficacy in patients with advanced breast cancer; however, predictive and prognostic biomarkers for treatment outcomes remain poorly defined. Host immune status has been reported to influence the efficacy of various systemic therapies, but its clinical significance in patients treated with T-DXd is not yet fully understood.

Methods

We conducted a retrospective, single-center study of patients with breast cancer who received T-DXd. Their baseline peripheral blood immune markers—including absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio—were evaluated prior to treatment initiation. Time-to-treatment failure (TTF) and overall survival (OS) were analyzed using Kaplan–Meier methods and Cox proportional hazards models.

Results

A total of 126 patients were included in the study. Univariate analyses showed that low ALC and high NLR were associated with shorter TTF and OS. In multivariate analyses adjusted for relevant clinical factors, low ALC and high NLR remained associated with shorter TTF and OS.

Conclusions

Baseline peripheral blood immune markers, particularly ALC and NLR, may be associated with clinical outcomes in patients with breast cancer treated with T-DXd. These readily available markers may have potential clinical utility and warrant further prospective validation.